secwatch / observer
8-K filed May 18, 2026, 8:00 AM ET ticker KYTX CIK 0001994702
leadership confidence high sentiment neutral materiality 0.70

Kyverna appoints Greg Martini as CFO; Marc Grasso transitions to strategic advisor

Kyverna Therapeutics, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gregory Martini

Chief Financial Officer
KYTX · Kyverna Therapeutics, Inc.
Effective
2026-05-18
Filed
May 18, 2026, 8:00 AM ET
On May 14, 2026, the Board of Directors (the “Board”) of Kyverna Therapeutics, Inc. (the “Company”) appointed Gregory Martini as the Company’s Chief Financial Officer, effective May 18, 2026 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gregory Martini was appointed as Chief Financial Officer at Kyverna Therapeutics, Inc..

Action
appointed
Role
Chief Financial Officer
Exact text from the filing
On May 14, 2026, the Board of Directors (the “Board”) of Kyverna Therapeutics, Inc. (the “Company”) appointed Gregory Martini as the Company’s Chief Financial Officer, effective May 18, 2026 (the “Effective Date”).
View on SEC.gov

Kyverna Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-26-227920
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.